Ruxolitinib in acute and chronic graft-versus-host disease: real life long-term experience in a multi-center study for adult and pediatric patients, on behalf of the GETH-TC


Por: Escamilla-Gómez V, García Gutiérrez V, Alcalde-Mellado P, Astibia-Mahillo B, Chinea-Rodriguez A, López-Corral L, Acera-Gómez M, Torres Ochando MK, Borrero Borrego A, González Pinedo L, Zudaire Ripa T, González Vicent M, Benzaquén A, Izquierdo Garcia I, Asensi Cantó P, Montoro J, Martín-Domínguez FM, Orti G, Valcárcel D, Benitez-Carabante MI, Diaz-de-Heredia C, Cañamero E, Ferrá C, García-Cadenas I, Redondo S, Sisinni L, Perez-Martínez A, Mussetti A, Garcia-Mañó L, Palomo-Moraleda MDP, González-Sierra PA, Jurado M and Perez-Simon JA

Publicada: 1 mar 2025 Ahead of Print: 1 dic 2024
Resumen:
Ruxolitinib has been approved for the treatment of adults and pediatric patients >= 12 years with steroid refractory graft-versus-host disease (GvHD). However, real-life studies are needed to confirm the results of clinical trials and further assess its efficacy in special populations. We performed a descriptive, retrospective, multi-center study of 352 adults and 42 pediatric patients treated with ruxolitinib for steroid-refractory acute or chronic GvHD. Among 119 and 233 adult patients with acute and chronic GvHD, overall response rate (ORR) was 58.8% (CR 33.6%) and 65.7% (CR 18.5%), respectively. Corticosteroids were withdrawn in 59.2% and 40.1%, and ruxolitinib in 47.2% and 34.8% in the acute and chronic groups of responders. Among 29 and 13 pediatric patients with acute and chronic GvHD, ORR was 82.7% (CR 51.7%) and 100% (CR 23%), respectively. Among responder patients, corticosteroids were withdrawn in 72.7% and 50%, and ruxolitinib in 75% and 30.7% in both groups respectively. Ruxolitinib in the real world setting, showed similar results as compared to clinical trials. Its efficacy is maintained in subsequent lines of treatment. In the pediatric population, the data are more favorable. In the long-term follow-up, corticosteroids, ruxolitinib and other inmunosuppressive drugs could be eliminated in a remarkably proportion of patients.

Filiaciones:
Escamilla-Gómez V:
 Servicio de hematologia, Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS)/CSIC, Universidad de Sevilla, Sevilla, Spain

García Gutiérrez V:
 Hematology Service, Hospital Universitario Ramón y Cajal. IRYCIS, Universidad de Alcalá, Madrid, Spain

Alcalde-Mellado P:
 Servicio de hematologia, Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS)/CSIC, Universidad de Sevilla, Sevilla, Spain

Astibia-Mahillo B:
 Hematology Service, Hospital Universitario Ramón y Cajal. IRYCIS, Universidad de Alcalá, Madrid, Spain

Chinea-Rodriguez A:
 Hematology Service, Hospital Universitario Ramón y Cajal. IRYCIS, Universidad de Alcalá, Madrid, Spain

López-Corral L:
 Department of Hematology, Hospital Clínico Universitario de Salamanca (CAUSA/IBSAL), Salamanca, Spain

Acera-Gómez M:
 Department of Hematology, Hospital Clínico Universitario de Salamanca (CAUSA/IBSAL), Salamanca, Spain

Torres Ochando MK:
 Hematology Department, Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, Spain

Borrero Borrego A:
 Hematology Department, Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, Spain

González Pinedo L:
 Hematology Department, Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, Spain

Zudaire Ripa T:
 Hematology Department, Hospital Universitario de Navarra, Pamplona, Spain

González Vicent M:
 Hematopoietic Transplant Department, Hospital Universitario Niño Jesús, Madrid, Spain

Benzaquén A:
 Hematology Department, Hospital Clínico Universitario de Valencia, Instituto de Investigación Sanitaria INCLIVA, Valencia, Valencia, Spain

Izquierdo Garcia I:
 Hematology Department, Hospital Universitario Miguel Servet, Zaragoza, Spain

Asensi Cantó P:
 Hematology Department, Hospital Universitario y Politécnico La Fe, Valencia, Spain

Montoro J:
 Hematology Department, Hospital Universitario y Politécnico La Fe, Valencia, Spain

Martín-Domínguez FM:
 Servicio de hematologia, Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS)/CSIC, Universidad de Sevilla, Sevilla, Spain

Orti G:
 Hematology Department, HospitalUniversitario Vall d´Hebron, Barcelona, Spain

Valcárcel D:
 Hematology Department, HospitalUniversitario Vall d´Hebron, Barcelona, Spain

Benitez-Carabante MI:
 Hematology and Oncology Department, Division of Pediatric Hematology and Oncology, Hospital Universitario Vall d´Hebron, Barcelona, Spain

Diaz-de-Heredia C:
 Hematology and Oncology Department, Division of Pediatric Hematology and Oncology, Hospital Universitario Vall d´Hebron, Barcelona, Spain

Cañamero E:
 Hematology Deparment, HospitalUniversitario Germans Trias i Pujol - Institut Català d'Oncologia, Barcelona, Spain

:
 Hematology Deparment, HospitalUniversitario Germans Trias i Pujol - Institut Català d'Oncologia, Barcelona, Spain

García-Cadenas I:
 Hematology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

Redondo S:
 Hematology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

Sisinni L:
 Hemato-Oncology Pediatric Service, HospitalUniversitario La Paz, Madrid, Spain

Perez-Martínez A:
 Hemato-Oncology Pediatric Service, HospitalUniversitario La Paz, Madrid, Spain

Mussetti A:
 Department of Hematology, Hospital Duran i Reynals, Instituto Catalán de Oncología, L'Hospitalet De Llobregat, Barcelona, Spain

Garcia-Mañó L:
 Hospital Universitario Son Espases, Islas Baleares, Spain

Palomo-Moraleda MDP:
 Hematology Department, Hospital Universitario Central de Asturias, Oviedo, Spain

González-Sierra PA:
 Hospital Universitario Virgen de las Nieves, Instituto de Investigación Biosanitaria, Granada, Spain

Jurado M:
 Hospital Universitario Virgen de las Nieves, Instituto de Investigación Biosanitaria, Granada, Spain

Perez-Simon JA:
 Servicio de hematologia, Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS)/CSIC, Universidad de Sevilla, Sevilla, Spain
ISSN: 02683369





Bone Marrow Transplantation
Editorial
Nature Publishing Group, MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND, Reino Unido
Tipo de documento: Article
Volumen: 60 Número: 3
Páginas: 353-362
WOS Id: 001375348600001
ID de PubMed: 39663471

MÉTRICAS